Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8528379 | Clinical Therapeutics | 2017 | 11 Pages |
Abstract
Patient interviews revealed that TELESTAR patients, at baseline, were significantly affected by their high BM frequency. Patient reports of their clinical trial experience supported the significance of the primary end point and clinical responder analysis in TELESTAR, helping identify and understand clinically meaningful change produced by telotristat ethyl.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Lowell MD, Claire MPH, Pablo MD, Matthew H. MD, Pamela MD, Emily MD, Dieter MD, David C. MD, Janice MD, Nick MD, Marianne MD, Martyn MD, Kjell MD, PhD, John MD, Emily MPA, Qi Melissa PhD, Shanna RN, MBA, CCRA, Karie BS, Dana B. PhD,